Abrupt Discontinuation of Propranolol

Phase 3

Abrupt Discontinuation of Propranolol is one of 2 therapeutic programs targeting Infantile Hemangioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Infantile HemangiomaNot yet recruiting

Infantile HemangiomaPhase 3

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Infantile Hemangioma

#DrugCompanyPhaseTrials

Abrupt Discontinuation of Propranolol

WWest China Hospital

Phase 3

1 2

Inderal

WWyeth-Lederle Vaccines

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

ApprovedNot yet recruiting

Infantile Hemangioma

NCT07665177

Clinical

Trials by Indication[1]

Infantile Hemangioma1 trial

Rebound Growth After Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma: A Multicenter Randomized Noninferiority Trial

Not yet recruiting·WWest China Hospital·Approved·NCT07665177·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Abrupt Discontinuation of Propranolol. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Abrupt Discontinuation of Propranolol. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: WWest China Hospital

Abrupt Discontinuation of Propranolol

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Infantile Hemangioma1 trial

References

Drug Info

Quick Facts

Related News